Advertisement

Organisation › Details
Silence Therapeutics (Group)
Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including reduced cytokine induction and decreased manufacturing costs. Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets. The Company's lead internal drug candidate is Atu027, a liposomal AtuRNAi formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutics in the area of oncology. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as, repeated intravenous administration. The study is expected to be completed in the second half of 2011. The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer, and Quark. Silence is actively pursuing the establishment of additional partnerships. *
![]() |
Start | 2007-04-26 renamed |
Predecessor | SR Pharma (Group) | |
![]() |
Industry | RNAi drug (RNAi therapeutic) |
Industry 2 | SLN124 (Silence Therapeutics) | |
![]() |
Person | Tooman, Craig A. (Silence Therapeutics 202202– CEO joined 1/21 before Vyome Tx + Aratana Tx + Avanzar Medical + Enzon) |
Person 2 | Hellums, Rhonda (Silence Therapeutics 202202– CFO joined 4/21 before KCI + Genzyme + Deer Oaks Mental Health + Aratana) | |
![]() |
Region | London, Greater London |
Country | United Kingdom (GB) | |
Street | 72 Hammersmith Road | |
City | W14 8TH London | |
Tel | +44-20-3457-6900 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2023-12-31) |
Currency | GBP | |
Annual sales | 25,375,000 (revenue, consolidated (2023) 2023-12-31) | |
Profit | -43,267,000 (2023-12-31) | |
Cash | 54,031,000 (2023-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-06-25 |
Advertisement

More documents for Silence Therapeutics (Group)
- [1] Silence Therapeutics plc. (2/5/24). "Press Release: Silence Therapeutics Announces Oversubscribed $120 Million Private Placement". London....
- [2] Silence Therapeutics plc. (1/31/24). "Press Release: Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference". London....
- [3] Silence Therapeutics plc. (2/21/22). "Press Release: Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer. Mark Rothera Steps Down as President and CEO". London....
- [4] Gubra ApS. (2/10/22). "Press Release: Gubra ApS and Silence Therapeutics plc Collaborate to Develop RNAi Therapies against Novel Liver-directed Targets from Gubra’s streaMLine Platform". Hørsholm....
- [5] Silence Therapeutics plc. (10/15/21). "Press Release: Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform". London & Shanghai....
- [6] Silence Therapeutics plc. (3/25/20). "Press Release: Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics for Cardiovascular, Renal, Metabolic and Respiratory Diseases". London....
- [7] Silence Therapeutics plc. (3/25/20). "Press Release: Silence Therapeutics Announces R&D Update". London....
- [8] Silence Therapeutics plc. (8/5/19). "Press Release: Silence Therapeutics Appoints Jørgen Wittendorff as Head of Manufacturing". London....
- [9] Silence Therapeutics plc. (7/18/19). "Press Release: Silence Therapeutics and Mallinckrodt Announce Collaboration to Develop and Commercialize RNAi Therapeutics for Complement-mediated Diseases". London & Staines-upon-Thames....
- [10] Silence Therapeutics plc. (7/18/19). "Press Release: Mallinckrodt to Make an Equity Investment in Silence Therapeutics as Part of a Collaboration". London & Staines-upon-Thames....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top